Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug ...
On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of global harmonization and streamlining biosimilar development during a panel ...
Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback